FDA Letter API

Best Bentonite

Letter data

Company
Best Bentonite
Recipient
Marshall A. Dunlap | Owner | Best Bentonite | Best Bentonite | 11650 Otis Rd | Guthrie | , | OK | 73044 | United States
Issue date
2018-11-23
Posted date
Not available
FDA office
United States
Subject
Not available
Product
Drugs
CMS ID
494502
Reference number
2016-DAL-WL-26
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Best Bentonite MARCS-CMS 494502 — November 23, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: UPS NEXT DAY DELIVERY Reference #: 2016-DAL-WL-26 Product: Drugs Recipient: Recipient Name Marshall A. Dunlap Recipient Title Owner Best Bentonite Best Bentonite 11650 Otis Rd Guthrie , OK 73044 United States Issuing Office: United States Marshall A. Dunlap - Owner Best Bentonite 11650 Otis Rd Guthrie, OK 73044 Mr. Dunlap: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 2016-DAL-WL-26 dated June 17, 2016. Based on our evaluation during, it appears that you have addressed the violations contained in this Warning Letter related to your marketing of Best Bentonite. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ LCDR John W. Diehl, M.S. Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II Content current as of: 11/30/2018 Regulated Product(s) Drugs